The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...
GlobalData on MSN7h
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drugNovo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are ...
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...
A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic dermatitis and psoriasis in a skin biopsy, according to a press release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback